186 related articles for article (PubMed ID: 25113163)
1. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.
Saintes C; Saint-Jean M; Renaut JJ; Dréno B; Quéreux G
Br J Dermatol; 2015 Mar; 172(3):819-21. PubMed ID: 25113163
[No Abstract] [Full Text] [Related]
2. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
3. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):12-4. PubMed ID: 24852791
[No Abstract] [Full Text] [Related]
5. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
6. A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
Corey K; Cook D; Bekker J; Mugnaini E; Lin JH
JAMA Dermatol; 2014 Feb; 150(2):210-2. PubMed ID: 24352253
[No Abstract] [Full Text] [Related]
7. CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases.
Mody K; Wallace JS; Stearns DM; Bowers G; Lacy SR; Levy NB; Zug KA; Lansigan F
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):319-23. PubMed ID: 23313068
[No Abstract] [Full Text] [Related]
8. Brentuximab vedotin in CD30
Stranzenbach R; Dippel E; Schlaak M; Stadler R
Br J Dermatol; 2017 Dec; 177(6):1503-1509. PubMed ID: 28703284
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
10. Primary cutaneous aggressive epidermotropic cytotoxic CD8
Cyrenne BM; Subtil A; Girardi M; Foss F
Int J Dermatol; 2017 Dec; 56(12):1448-1450. PubMed ID: 29047111
[No Abstract] [Full Text] [Related]
11. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):10-1. PubMed ID: 24870875
[No Abstract] [Full Text] [Related]
12. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.
Lewis DJ; Talpur R; Huen AO; Tetzlaff MT; Duvic M
JAMA Dermatol; 2017 Dec; 153(12):1302-1306. PubMed ID: 28980004
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
14. Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma.
Aldaoud A
Dermatol Clin; 2008 Jan; 26 Suppl 1():15-7. PubMed ID: 18405181
[No Abstract] [Full Text] [Related]
15. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
Gualberto A
Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
19. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.
Fromm JR; McEarchern JA; Kennedy D; Thomas A; Shustov AR; Gopal AK
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):280-3. PubMed ID: 22542449
[No Abstract] [Full Text] [Related]
20. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
